Quantitative image analysis of intra-tumoral bFGF level as a molecular marker of paclitaxel resistance

Journal of Translational Medicine

Volumn 6, Issue , 2008, Pages

  Walsh, Colin T ^a   Wei, Yong ^a   Wientjes, M Guillaume ^a,b   Au, Jessie L S ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; MOLECULAR MARKER; PACLITAXEL; ANTINEOPLASTIC AGENT; FIBROBLAST GROWTH FACTOR 2; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; BREAST CANCER; CHEMOSENSITIVITY; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEAD AND NECK CANCER; HORMONE BLOOD LEVEL; HORMONE URINE LEVEL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; OVARY CANCER; PROGNOSIS; PROSTATE CANCER; QUANTITATIVE ANALYSIS; SCORING SYSTEM; TUMOR XENOGRAFT; ANIMAL; CELL CULTURE; CELL PROLIFERATION; CELL STRAIN HT29; COMPARATIVE STUDY; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; IC 50; IMAGE PROCESSING; METHODOLOGY; MOUSE MUTANT; PANCREAS TUMOR; PATHOLOGY; PHARYNX CANCER; PROSTATE TUMOR; SENSITIVITY AND SPECIFICITY; STATISTICS; TISSUE CULTURE TECHNIQUE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLAST GROWTH FACTOR 2; HT29 CELLS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; INHIBITORY CONCENTRATION 50; MALE; MICE; MICE, SCID; PACLITAXEL; PANCREATIC NEOPLASMS; PHARYNGEAL NEOPLASMS; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; STATISTICS AS TOPIC; TISSUE CULTURE TECHNIQUES; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 41049114818     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-6-4     Document Type: Article

References (24)

1. Nygren P Larsson R Overview of the clinical efficacy of investigational anticancer drugs J Intern Med 2003, 253:46-75. 10.1046/ j.1365-2796.2003.01098.x 12588538
2. Croom KF Perry CM Imatinib mesylate: In the treatment of gastrointestinal stromal tumours Drugs 2003, 63:513-522. 10.2165/ 00003495-200363050-00005 12600228
3. Deininger M Buchdunger E Druker BJ The development of imatinib as a therapeutic agent for chronic myeloid leukemia Blood 2005, 105:2640-2653. 10.1182/blood-2004-08-3097 15618470
4. Eiermann W Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: Pivotal trial data Ann Oncol 2001, 12(Suppl1):S57-S62. 10.1023/A:1011172125897 11521723
5. Hirsch FR Varella-Garcia M Bunn PA Jr Franklin WA Dziadziuszko R Thatcher N Chang A Parikh P Pereira JR Ciuleanu T von Pawel J Watkins C Flannery A Ellison G Donald E Knight L Parums D Botwood N Holloway B Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer J Clin Oncol 2006, 24:5034-5042. 10.1200/JCO.2006.06.3958 17075123
6. Song S Wientjes MG Walsh C Au JL Nontoxic doses of suramin enhance activity of paclitaxel against lung metastases Cancer Res 2001, 61:6145-6150. 11507065
7. Coleman AB Positive and negative regulation of cellular sensitivity to anti-cancer drugs by FGF-2 Drug Resist Updat 2003. 6:85-94. 10.1016/ S1368-7646(03)00023-2 12729806
8. Huang A Wright JA Fibroblast growth factor mediated alterations in drug resistance, and evidence of gene amplification Oncogene 1994, 9:491-499. 7904743
9. Huang A Jin H Wright JA Aberrant expression of basic fibroblast growth factor in NIH-3T3 cells alters drug resistance and gene amplification potential Exp Cell Res 1994, 213:335-339. 10.1006/excr.1994.1207 8050490
10. Ohta T Yamamoto M Numata M Iseki S Tsukioka Y Miyashita T Kayahara M Nagakawa T Miyazaki I Nishikawa K Yoshitake Y Expression of basic fibroblast growth factor and its receptor in human pancreatic carcinomas Br J Cancer 1995, 72:824-831. 7547227
11. Volm M Koomagi R Mattern J Stammler G Prognostic value of basic fibroblast growth factor and its receptor (FGFR-1) in patients with non-small cell lung carcinomas Eur J Cancer 1997, 33:691-693. 10.1016/ S0959-8049(96)00411-X 9274456
12. Faridi A Rudlowski C Biesterfeld S Schuh S Rath W Schroder W Long-term follow-up and prognostic significance of angiogenic basic fibroblast growth factor (bFGF) expression in patients with breast cancer Pathol Res Pract 2002, 198:1-5. 10.1078/0344-0338-00176 11866204
13. Blanckaert VD Hebbar M Louchez MM Vilain MO Schelling ME Peyrat JP Basic fibroblast growth factor receptors and their prognostic value in human breast cancer Clin Cancer Res 1998, 4:2939-2947. 9865904
14. Colomer R Aparicio J Montero S Guzman C Larrodera L Cortes-Funes H Low levels of basic fibroblast growth factor (bFGF) are associated with a poor prognosis in human breast carcinoma Br J Cancer 1997, 76:1215-1220. 9365172
15. Linderholm BK Lindh B Beckman L Erlanson M Edin K Travelin B Bergh J Grankvist K Henriksson R Prognostic correlation of basic fibroblast growth factor and vascular endothelial growth factor in 1307 primary breast cancers Clin Breast Cancer 2003, 4:340-347. 14715109
16. Smith K Fox SB Whitehouse R Taylor M Greenall M Clarke J Harris AL Upregulation of basic fibroblast growth factor in breast carcinoma and its relationship to vascular density, oestrogen receptor, epidermal growth factor receptor and survival Ann Oncol 1999, 10:707-713. 10.1023/ A:1008303614441 10442194
17. Yiangou C Gomm JJ Coope RC Law M Luqmani YA Shousha S Coombes RC Johnston CL Fibroblast growth factor 2 in breast cancer: Occurrence and prognostic significance Br J Cancer 1997, 75:28-33. 9000594
18. Obermair A Speiser P Reisenberger K Ullrich R Czerwenka K Kaider A Zeillinger R Miksche M Influence of intratumoral basic fibroblast growth factor concentration on survival in ovarian cancer patients Cancer Lett 1998, 130:69-76. 10.1016/S0304-3835(98)00119-0 9751258
19. Bredel M Pollack IF Campbell JW Hamilton RL Basic fibroblast growth factor expression as a predictor of prognosis in pediatric high-grade gliomas Clin Cancer Res 1997, 3:2157-2164. 9815610
20. Gan Y Wientjes MG Au JL Expression of basic fibroblast growth factor correlates with resistance to paclitaxel in human patient tumors Pharm Res 2006, 23:1324-1331. 10.1007/s11095-006-0136-6 16741658
21. Gan Y Wientjes MG Schuller DE Au JL Pharmacodynamics of taxol in human head and neck tumors Cancer Res 1996, 56:2086-2093. 8616855
22. Snedecor W George Cochran G William Statistical Methods Ames, Iowa: The Iowa State University Press 7 1980
23. Greenblatt MS Bennett WP Hollstein M Harris CC Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis Cancer Res 1994, 54:4855-4878. 8069852
24. Song S Wientjes MG Gan Y Au JL Fibroblast growth factors: An epigenetic mechanism of broad spectrum resistance to anticancer drugs Proc Natl Acad Sci USA 2000, 97:8658-8663. 27004 10890892 10.1073/pnas.140210697